Hero Brain Health and the eTMS approach have been gaining attention across the country – from news media coverage, to legislative briefings, to features in medical journals.
We believe in keeping the public informed about our work and celebrating the growing recognition of this therapy’s impact. Below are some highlights of recent media and news items related to eTMS and our mission:
Spectrum Bay News 9 in Florida profiled an eTMS clinic and its patients, calling the treatment “life changing” for veterans and first responders. The story highlighted Navy veteran John Doolittle, who after years of severe insomnia now sleeps 7–8 hours a night thanks to eTMS. The segment also noted that patients receive the treatment free of charge through the state-supported program and typically undergo 20 sessions (five days a week over four weeks). It featured on-camera testimonials, including a technician who observed, “We’re literally seeing people’s personalities come back…They’re entirely new people – just happier and mentally healthier.” This kind of local news coverage underscores the real-world impact and human interest in eTMS. (Search for “eTMS Florida Spectrum News” to watch the full story.)
CBS affiliate KCTV5 News covered the launch of an eTMS clinic in Kansas City, Missouri, which operates under a state pilot program. The news story included interviews with program staff and participants, describing the treatment as “lifesaving” and focusing on its ripple effect in the community. One key point reported was that about 85–90% of treated individuals see results, with symptom reduction in the 55–70% range, based on the program’s early data. “Our results are better than most other modalities out there,” said the clinical director, noting that they are changing lives “without putting people through years of counseling or heavy meds”. The news segment also showed state legislators touring the facility and expressed that expansion into neighboring states (like Kansas) was being pursued. Such coverage not only informs the public but also serves as a call to action for lawmakers: indeed, program managers publicly invited senators and representatives to come see the success for themselves. This aligns perfectly with Hero Brain Health’s approach – we welcome dialogue with officials and stakeholders to secure support for making these treatments widely available.
Dr. Erik Won, president of Wave Neuroscience (our technology partner), testified on the eTMS program before the Ohio House Health Committee. In his testimony, Dr. Won shared the outcomes of Ohio’s eTMS pilot, including the impressive PTSD improvement rates: eTMS showed a 63% improvement on PTSD scores, compared to roughly 30% with standard TMS and even lower with medication alone. He also highlighted successes in addressing substance use (with eTMS reducing alcohol and opioid cravings by over 55–60% in pilot studies). In June 2026, the FDA went on to clear Wave's EEG-guided system as an adjunct treatment for adults with PTSD. Ohio’s legislative interest and subsequent budget funding for eTMS have been influential, setting a precedent that Hero Brain Health is hoping to replicate in our region. We make it a point to keep our elected officials apprised of our outcomes, and we are encouraged to see bipartisan support growing for innovative treatments like this.
eTMS is also making waves in the scientific community. In addition to the 2015 study mentioned in our Data section, more papers are being published that validate and refine this approach. For example, Frontiers in Neurology (Feb 2025) published Frueh et al.’s study of 33 special operations veterans, which reported “significant reductions in TBI clinical symptoms as well as significant decreases in PTSD clinical severity” and recommended further clinical trials. Frontiers in Psychiatry (June 2024) featured Bailar-Heath et al.’s report on 18 active-duty service members, finding a 37% reduction in PTSD symptoms with EEG-guided TMS and no serious side effects. Most recently, Neuropsychiatric Disease and Treatment (Sept 2026) published a review of 94 military service members showing a 48% reduction in PTSD symptoms and a 52% reduction in depression symptoms. These publications in reputable journals lend clinical credibility to what we do at Hero Brain Health. We are essentially translating this body of research into practice for our patients. Our team stays up-to-date with the latest findings and is often involved in collaborative studies. By being part of a larger research network (through Wave Neuroscience and partnering universities), we ensure that our treatment protocols are always informed by the newest evidence. This means you are receiving cutting-edge care that’s vetted by experts worldwide.
The U.S. Department of Defense and Veterans Affairs have shown increasing interest in eTMS as an adjunct or alternative to traditional treatments. There are ongoing DoD-supported clinical trials – for instance, studies at Virginia Tech and Wright State University are currently recruiting veterans to formally evaluate the efficacy of this technology for PTSD. Furthermore, military medical conferences have featured presentations on eTMS (sometimes called MeRT or “alpha-targeted rTMS”), with Air Force and Special Operations medical units sharing anecdotal successes. The Air Force Special Operations Command (AFSOC) has internally referred to these therapies in the context of their human performance programs aimed at addressing operator PTSD/TBI. We anticipate that in the near future, organizations like the VA will develop protocols to offer EEG-guided TMS in VA hospitals, especially if the current trials continue to show positive results. Hero Brain Health is positioning itself to be a leader in this space, possibly serving as a training and demonstration site for government and VA healthcare providers interested in adopting eTMS. Being in Boston – a hub for medical innovation – we are also exploring partnerships with academic medical centers and veteran service organizations to further validate and expand access to our program.
Hero Brain
Health, LLC
22 Kent Street
Somerville, MA 02143
